Zobrazeno 1 - 10
of 139
pro vyhledávání: '"D. Voliotis"'
Autor:
Anthony W. Tolcher, F. Donate, Pavani Chalasani, M. Sergeeva, D. Voliotis, Funda Meric-Bernstam, H. Mamdani, P. Pultar, Mihaela Gazdoiu, A.A. Samatar, K. Anderes, M.R. Viana, P.R. de Jong
Publikováno v:
Annals of Oncology. 32:S593
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bac25146fc65e8cea397950efe4e684e
https://doi.org/10.1016/j.annonc.2021.08.1048
https://doi.org/10.1016/j.annonc.2021.08.1048
Autor:
H.-J. Shin, R. Kirshoff, Jan Maciej Zaucha, G. Gordon, N. Viiala, L. Torres, S-L Park, A. Kalro, L. Makris, S. Lopez, C. Miller, D. Voliotis, T. Fiorino
Publikováno v:
Annals of Oncology. 32:S617
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::939752ea47fca54198a395f3399ed934
https://doi.org/10.1016/j.annonc.2021.08.1083
https://doi.org/10.1016/j.annonc.2021.08.1083
Autor:
P.R. de Jong, Siquing Fu, P. Pultar, J. Rodriguez, Tarek Meniawy, A.A. Samatar, G. Richardson, F. Donate, Z.J. Vranjes, D. Voliotis, Anes Pasic
Publikováno v:
Annals of Oncology. 32:S618
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f891103fe8216e15aa9038d78bc90e6c
https://doi.org/10.1016/j.annonc.2021.08.1084
https://doi.org/10.1016/j.annonc.2021.08.1084
Autor:
Jessie Zou, Yoon-Koo Kang, Jiwei Liu, Chao Jung Tsao, Ann-Lii Cheng, Jun Suk Kim, Karin Burock, Jiejun Wang, Houjie Liang, Rongcheng Luo, Jianming Xu, Shukui Qin, Zhongzhen Guan, Jifeng Feng, Yan Sun, D. Voliotis, Sheng-Long Ye, Hongming Pan, Tsai Sheng Yang, Zhendong Chen, Won Young Tak
Publikováno v:
The Lancet Oncology. 10:25-34
Summary Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and safety of new therapeutic options in an Asia-Pacific popul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45eed098d16f912b598d6e6c51e3c501
https://doi.org/10.1016/s1470-2045(08)70285-7
https://doi.org/10.1016/s1470-2045(08)70285-7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S. Steinbild, E. Brendel, Martin Radtke, D. Voliotis, Clemens Unger, O. Christensen, Klaus Mross, F. Baas, D. Gmehling
Publikováno v:
European Journal of Cancer. 43:55-63
Purpose This single-centre, open-label, phase I dose-escalation study was performed to investigate the safety, pharmacokinetics (PK) and efficacy of sorafenib, a multi-kinase inhibitor, combined with irinotecan, a cytotoxic agent, in patients with ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a736a7917915f8eadba40e84d7d7e5
https://doi.org/10.1016/j.ejca.2006.08.032
https://doi.org/10.1016/j.ejca.2006.08.032
Autor:
E Hofstra, Dirk Strumberg, D. Voliotis, O. Christensen, Hal W. Hirte, P Piccart, Ahmad Awada, Jeffrey W. Clark, Andreas Brueckner, Siegfried Seeber, Brian Schwartz
Publikováno v:
European Journal of Cancer. 42:548-556
In this analysis of the safety and efficacy of BAY 43-9006 (sorafenib) -- a novel, oral multi-kinase inhibitor with effects on tumour and its vasculature -- pooled data were obtained from four phase I dose-escalation trials. Time to progression (TTP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9586e9e27484a61b6f2efe8cdfcee63
https://doi.org/10.1016/j.ejca.2005.11.014
https://doi.org/10.1016/j.ejca.2005.11.014
Autor:
Max E. Scheulen, Mitra Tewes, Ralf A. Hilger, D. Voliotis, E. Brendel, Norbert Schleucher, Rudolf Voigtmann, Dirk Strumberg, Brian Schwartz, Markus Faghih, Ahmad Awada, Siegfried Seeber, C. G. Haase, Sonke Korfee, Heike Richly
Publikováno v:
Journal of Clinical Oncology. 23:965-972
Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a803f247bc5cc861e64703f2618254
https://doi.org/10.1200/jco.2005.06.124
https://doi.org/10.1200/jco.2005.06.124
Autor:
Mariam Scharifi, Jochen Zisowsky, D. Voliotis, Ulrich Jaehde, Martina Heim, Siegfried Seeber, Dirk Strumberg
Publikováno v:
Anti-Cancer Drugs. 16:129-136
Raf kinase plays a central role in oncogenic signaling and acts as a downstream effector of Ras in the extracellular signal-regulated (ERK) kinase pathway. BAY 43-9006 (BAY) is a novel signal transduction inhibitor that prevents tumor cell proliferat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b711cb25ac284e51200e31d5fdc9f01
https://doi.org/10.1097/00001813-200502000-00003
https://doi.org/10.1097/00001813-200502000-00003
Autor:
Dirk Strumberg, N. Schleucher, E. Brendel, U. Sauer, D. Voliotis, Heike Richly, Clemens Unger, Max E. Scheulen, T. Beinert, Siegfried Seeber, Klaus Mross, M. Schweigert, Dirk Behringer, C. G. Haase, M. Tewes, S. Korfee
Publikováno v:
Annals of Oncology. 15:1284-1294
Background: The aim of this study was to define the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetics of the camptothecin glycoconjugate BAY 38-3441, administered as an infusion for 30 min on two separate schedules every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81098df4ed105969ee85a049b2d033d
https://doi.org/10.1093/annonc/mdh313
https://doi.org/10.1093/annonc/mdh313